Cost-effectiveness of first-line zanidatamab plus chemotherapy with or without tislelizumab for HER2-positive advanced gastroesophageal adenocarcinoma in China
Frontiers in Pharmacology · 19.11.2026 · 17
DOI: 10.3389/fphar.2026.1951956 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 19.11.2026. Verfasst von Mei Zhou und 6 weiteren Autor:innen. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
Objective
To evaluate the cost-utility of first-line zanidatamab plus chemotherapy, with or without tislelizumab, versus trastuzumab plus chemotherapy for HER2-positive advanced gastroesophageal adenocarcinoma from the Chinese healthcare-system perspective.
Methods
A partitioned survival model informed by HERIZON-GEA-01 was developed over a 10-year horizon. Costs and health outcomes were discounted at 4.5% annually. Base-case analysis compared costs and quality-adjusted life years (QALYs) across all three strategies and assessed incremental cost-utility. Deterministic and probabilistic sensitivity analyses assessed parameter uncertainty, including survival parameters. Scenario analyses examined alternative survival extrapolations, 5- and 15-year horizons, subsequent-treatment assumptions, adverse-event utility losses, and hypothetical patient assistance programs (PAPs). Price-threshold analyses identified the zanidatamab prices at which each strategy became preferred among all three alternatives. The primary willingness-to-pay threshold was USD 27,917.37/QALY, equivalent to twice China’s per capita GDP in 2025.
Results
Zanidatamab plus tislelizumab and chemotherapy, zanidatamab plus chemotherapy, and trastuzumab plus chemotherapy generated 2.2414, 1.7196, and 1.4737 QALYs at costs of USD 144,992.86, USD 105,313.53, and USD 29,633.07, respectively. Compared with trastuzumab plus chemotherapy, the corresponding incremental cost-utility ratios were USD 150,270.88/QALY and USD 307,767.29/QALY. Zanidatamab plus chemotherapy was subject to extended dominance. Sensitivity and scenario analyses, including the 5- and 15-year horizons, supported trastuzumab plus chemotherapy as the preferred strategy. Neither zanidatamab-containing regimen achieved positive incremental net monetary benefit in 5,000 probabilistic simulations at the primary threshold. Hypothetical PAPs reduced the pairwise incremental cost-utility ratios to USD 55,749.41/QALY and USD 106,806.31/QALY. Without PAP, simultaneous zanidatamab price reductions of approximately 76.13%–92.87% favored zanidatamab plus chemotherapy, while larger reductions favored the tislelizumab-containing regimen, with ties at boundary prices.
Conclusion
At the evaluated prices and primary willingness-to-pay threshold, neither zanidatamab-containing regimen was cost-effective in China. Substantial zanidatamab price reductions would be required to change the preferred strategy. Longer follow-up is needed to reassess uncertainty in long-term survival.
Zitieren
APA
Zhou, M., Zheng, Y., Ma, X., Man, H., Zhang, Y., Huo, L., & Feng, X. (2026). Cost-effectiveness of first-line zanidatamab plus chemotherapy with or without tislelizumab for HER2-positive advanced gastroesophageal adenocarcinoma in China. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1951956
Vancouver
Zhou M, Zheng Y, Ma X, Man H, Zhang Y, Huo L, et al. Cost-effectiveness of first-line zanidatamab plus chemotherapy with or without tislelizumab for HER2-positive advanced gastroesophageal adenocarcinoma in China. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.1951956
BibTeX
@article{Zhou2026,
author = {Zhou, Mei and Zheng, Ying and Ma, Xiaoyue and Man, Hongwei and Zhang, Yuehua and Huo, Liman and Feng, Xiaojie},
title = {Cost-effectiveness of first-line zanidatamab plus chemotherapy with or without tislelizumab for HER2-positive advanced gastroesophageal adenocarcinoma in China},
journal = {Frontiers in Pharmacology},
year = {2026},
volume = {17},
doi = {10.3389/fphar.2026.1951956}
}
EUVIMED